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Background—Hypertension is a common complication and is an important risk factor for graft
loss and adverse cardiovascular outcomes in pediatric kidney transplantation. Ambulatory blood
pressure monitoring (ABPM) is the preferred method to characterize blood pressure status.
Methods and Materials—We conducted a retrospective review of a large cohort of children and
young adults with kidney transplant to estimate the prevalence of abnormal ambulatory blood
pressure (ABP), assess factors associated with abnormal ABP, and examine whether ambulatory
hypertension is associated with worse allograft function and left ventricular hypertrophy (LVH).

Author Manuscript

Results—Two hundred and twenty-one patients had ABPM and 142 patients had
echocardiographic results available for analysis. One third of the patients had masked
hypertension, 32% had LVH, and 38% had estimated GFR<60ml/min/1.73m2. African-American
race/Hispanic ethnicity and requirement for more than one antihypertensive medication were
independently associated with having masked hypertension. In a multivariate analysis, abnormal
blood pressure (masked or sustained hypertension combined) was an independent predictor for
LVH among patients not receiving antihypertensive treatment (p=0.025). In a separate analysis, the
use of antihypertensive medications was independently associated with worse allograft function
(p=0.002), although abnormal blood pressure was not a significant predictor.
Conclusion—In young kidney transplant recipients, elevated ABP is frequently unrecognized
and undertreated. The high prevalence of abnormal ABP, including masked hypertension, and its
association with LVH supports the case for routine ABPM and cardiac structure evaluation as the
standard of care in these patients.

INTRODUCTION
Author Manuscript

Hypertension is a known common complication after pediatric kidney transplantation1,2,3
and is associated with worse short and long term graft function and with left ventricular
hypertrophy (LVH)4-7. Over the last two decades, ambulatory blood pressure monitoring
(ABPM) has been utilized more frequently to characterize blood pressure (BP) status in
patients with chronic kidney disease (CKD) because of its better ability to stratify
cardiovascular risk and predict progression of CKD8-12. Studies in pediatric kidney
transplant recipients have confirmed high prevalence of abnormal ambulatory blood pressure
(ABP), including masked hypertension, a condition characterized by normal BP in clinic but
elevated BP outside the medical provider’s office13-22. Yet, these published studies are
generally small, use different definitions of abnormal ABP, and most of them do not address
association of masked or sustained hypertension with allograft function or CV outcomes.

Author Manuscript

We conducted a study evaluating ABP patterns in a large cohort of kidney transplant
recipients from the Midwest Pediatric Nephrology Consortium (MWPNC) with the
following aims: 1) estimate the prevalence of ambulatory hypertension and assess factors
associated with abnormal ABP and 2) examine the association of ambulatory hypertension
with LVH and allograft function. We hypothesized that ambulatory hypertension would be
associated with LVH and worse allograft function.

Transplantation. Author manuscript; available in PMC 2018 January 01.
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MATERIALS AND METHODS
A retrospective analysis of children and young adults with kidney transplants who had
ABPM between January 2010 and December 2014 was carried out at 6 centers (via
collaboration through the MWPNC). The study was reviewed and approved by the
Institutional Review Boards of all participating centers.

Author Manuscript

Inclusion criteria were a functioning kidney transplant and age <23 years at the time of
ABPM. Charts were reviewed for demographic information (age, gender, race), etiology of
end-stage renal disease (glomerular versus structural/congenital), medications, history of
prior transplants, dialysis prior to transplant, prior episode of rejection), anthropometric
parameters (height, weight), casual blood pressure, and laboratory data (serum creatinine
and hemoglobin) at time of the first ABPM after transplantation. Medication information
collected specifically included all immunosuppressive agents and antihypertensive agents.
Allograft function was determined based on the bedside Schwartz formula for patients
younger than 18 years23 and CKD-EPI formula for patients 18-23 years24.
Echocardiographic data including left ventricular mass were collected, with analysis
restricted to subjects who received an echocardiogram within 6 months of ABPM. Left
ventricular hypertrophy was defined as left ventricular mass index (LVMI) ≥95th percentile
for age and gender25.
Spacelabs 90217 monitor (SpaceLabs Healthcare, Issaquah, WA) was used for all ABPM
studies. All centers utilized standard methodology to measure BP: for wake hours - every 20
minutes; for sleep hours measurements were performed either every 20 or 30 min.
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The ABP parameters of interest included mean systolic and diastolic BP for wake, sleep, and
24-hour periods. From this, systolic and diastolic BP dip status was determined by
calculating percent nocturnal drop in mean BP from waking mean values. In addition, wake
and sleep BP loads were calculated as the percent of readings at or above the 95th percentile,
based on published normative data26. Ambulatory BP index was calculated as the mean ABP
divided by the corresponding 95th percentile. Thus, an index of 1 indicates ABP equal to the
threshold value for a clinical diagnosis of hypertension, and an index of 1.1 is 10% above
that threshold27. Since the 95th percentile is gender and height specific, this measure allows
for comparison of BP across a wide range of pediatric normal values.

Author Manuscript

In this study, we applied the recently published American Heart Association (AHA) revised
classification of BP status in children according to casual blood pressure (CBP) and ABP
measurements28. Normal: CBP <90th percentile and mean daytime and nighttime, systolic
and diastolic ABP<95th percentile and BP load < 25%; White coat hypertension (WCH):
CBP≥95th percentile, mean daytime and nighttime, systolic and diastolic ABP<95th
percentile and BP load < 25%; Prehypertension: CBP ≥90th percentile or >120/80, mean
daytime and nighttime, systolic and diastolic ABP<95th percentile, BP load (daytime or
nighttime, systolic or diastolic) ≥ 25%; Masked hypertension: CBP <95th percentile, mean
daytime or nighttime, systolic or diastolic ABP ≥ 95th percentile, BP load ≥ 25%;
Ambulatory (sustained) hypertension: CBP ≥95th percentile, mean daytime or nighttime,
systolic or diastolic ABP ≥ 95th percentile, BP load ≥ 25%.
Transplantation. Author manuscript; available in PMC 2018 January 01.
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BP status was then re-classified using a different method based on the 24h measurements
(instead of day/and/or night separately), and using a BP load of >25% as the cutoff for
hypertension. This method allows classification of all patients into four simplified BP
categories (normal, WCH, masked, and sustained hypertension), and avoids several
situations in which the BP status is unclassified according to the AHA classification.
According to this classification, patients with CBP<95th percentile (normal/prehypertension)
and BP load ≥25% were classified as having masked hypertension, those with casual
prehypertension and normal ABP were classified as having normal BP, and those patients
with casual hypertension and BP load ≥25% were classified as having sustained
hypertension.
Statistical analysis

Author Manuscript

For descriptive statistics, categorical variables were reported as percentages, and continuous
variables reported as median and interquartile ranges. For univariate analyses, demographic
and clinical characteristics were compared between BP categories using chi-square testing
for categorical variables and the Wilcoxon rank-sum test for continuous variables. Logistic
regression was used to investigate the independent association of ABP status with LVH and
decreased allograft function (eGFR < 60 ml/min/1.73m2). All variables associated with an
eGFR < 60 ml/min/1.73m2 and LVH in univariate analyses (p < 0.15) were initially included
in the model. Backward elimination was performed to determine variables included in the
final model, with an inclusion criterion of p < 0.05. Odds ratios were reported for each
independent predictor along with Wald 95% confidence intervals. All statistical analyses
were performed using SAS 9.3 statistical software.

RESULTS
Author Manuscript

Cohort Characteristics
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Two hundred and twenty one kidney transplant recipients had ABPM results available for
analysis. Patient characteristics are summarized in Table 1. The majority were male and
white, and received a living donor kidney. One third of the cohort were young adults. One
hundred and fifty three patients were taking antihypertensive medications, and among them,
61% were taking one, 31% were taking two, and 7% were taking three BP medications; 67%
were on calcium-channel blockers, 40% on angiotensin-converting-enzyme inhibitors
(ACEI) or angiotensin-receptor-blockers (ARB), 25% on beta-blockers, and 5% were taking
diuretics. Among 142 patients who had an echocardiogram within six months of their
ABPM, 32% were found to have LVH. There was no significant difference in patient
characteristics between those who had and who did not have echocardiography except
higher hemoglobin level in the group without echocardiography (Supplemental Table).
Thirty-eight percent of the cohort had CKD stage 3-4.
Blood Pressure Classification
Blood pressure status is summarized in Table 2. According to CBP, 49% had normal BP,
34% had pre-hypertension, and 17% had hypertension. As expected, abnormal BP was
identified more frequently based on ABP measurements and, in large part related to

Transplantation. Author manuscript; available in PMC 2018 January 01.
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nocturnal hypertension, reaching 22-26% hypertensive based on mean ABP and with
42-45% hypertensive based on BP load.

Author Manuscript

ABP patterns based on the combination of CBP and ABP are shown in Figure 1. According
to the 2014 AHA classification (Figure 1A), 23% of the patients had normal BP. 12% had
pre-hypertension, 25% had masked hypertension, and 11% had sustained hypertension. Only
1% of the patients were classified as having WCH. The largest group of patients (28%) was
unclassified. This group was primarily composed of 1) patients with normal CBP, normal
mean ABP but elevated BP load, and 2) patients with casual pre-hypertension but normal
mean ABP results (mean BP <95th percentile and BP load <25%). Because many subjects
were unclassified using the AHA classification, we re-classified the patients into four BP
categories using 24-hour BP load ≥25% as the cutoff for hypertension (see methods).
According to this classification (Figure 1B), 51% of patients had normal BP, 32% had
masked hypertension, 14% had sustained hypertension, and 3% had WCH. Using this
classification, 31 (84%) of 37 of patients with casual hypertension were confirmed to have
sustained hypertension; among 76 patients with casual pre-hypertension, 40 (53%) had
normal ABP and 47% had masked hypertension. All subsequent analyses were done using
this classification.
Factors associated with abnormal ABP
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Patient characteristics according to their ABP/CBP status are summarized in Table 3. Both
patients with masked and sustained hypertension were more likely to be either of AfricanAmerican race or Hispanic ethnicity and were receiving more antihypertensive medications
than normotensive patients. Patients with sustained hypertension were younger, received
their transplant at a younger age, and were more likely to be on steroid treatment than those
with either normal BP or masked hypertension.
Blood pressure status and LVH
LVMI (median of 40 g/m2.7 vs. 34 g/m2.7, p=0.002) and the prevalence of LVH (50% vs.
28%, p=0.05) were higher in patients with sustained hypertension than in normotensive
patients. However, median LVMI (37 g/m2.7) and the prevalence of LVH (33%) in patients
with masked hypertension were similar to that observed in normotensive patients (Table 3).

Author Manuscript

Based on previous data suggesting patients with controlled hypertension (i.e., normotensive
and receiving blood pressure medications) have a different cardiovascular risk profile than
those without any history of hypertension17,20,29, BP status, LVMI and LVH were evaluated
according the use of antihypertensive medications (Table 4). Among patients receiving
antihypertensive medications, the distribution of patients amongst the BP categories was not
significantly different than that observed in patients not receiving treatment. However the
prevalence of LVH varied considerably between patients who were or were not on
antihypertensive medications. Patients with normal BP who were not taking antihypertensive
medications had the lowest LVMI (31g/m2.7) and prevalence of LVH (14%), while patients
with normal BP values but who were taking antihypertensive medications (i.e. controlled
hypertension) exhibited a median LVMI (37g/m2.7) and a prevalence of LVH (37%) similar
to patients with uncontrolled (either masked and sustained) hypertension. The differences
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among normotensive patients (normal BP and controlled hypertension) were seen despite
similar level of BP control (BP index and BP load) in these two groups (Table 4). Among
patients with controlled hypertension, there was no significant difference in the prevalence
of LVH according to class of BP medications (ACEI/ARB vs. others, p=0.68).
Multivariate logistic regression analysis was performed to evaluate the independent
association of BP status with LVH (Table 5). The interaction term Hypertension x BP
medication was significant (p<0.05), confirming a difference in the relationship between
hypertension and LVH in patients receiving and not receiving antihypertensive medication.
Hypertension was independently associated with LVH among those not receiving BP
treatment (OR 5.4; 95% CI 1.2 – 23.7, p=0.025). However, the OR for LVH in patients
receiving antihypertensive medications was 0.95 (95% CI, 0.38-2.39, p=0.91).

Author Manuscript

Blood pressure status and allograft function

Author Manuscript

Allograft function was significantly lower in patients with sustained hypertension than in
normotensive patients and those with masked hypertension; no significant difference was
found between patients with normal BP and masked hypertension (Table 3). When classified
according to antihypertensive medication status (Table 4), there was no significant difference
in graft function between normotensive and hypertensive patients (masked and sustained
combined) in the group not taking antihypertensive medications. However, patients taking
antihypertensive medications had significantly lower eGFR and higher prevalence of eGFR
<60 ml/min.1.73m2 than did patients in the group with normal BP or masked hypertension
not taking antihypertensive medications. No significant difference in allograft function was
found according to the class of antihypertensive medications (ACEI/ARB vs others, data not
shown). In a multivariate analysis, hypertension was not associated with allograft function
(Table 6). However, use of antihypertensive medications was independently associated with
having eGFR <60 ml/min.1.73m2 (OR 3.32, 95% CI: 1.6-6.9, p=0.002). In a sub-analysis,
this association remained significant regardless of the class of antihypertensive medications:
ACEI/ARB (OR 4.7, 95% CI: 2.0-11.2, p<0.001) or others (OR 2.5, 95% CI: 1.1-5.6,
p=0.024).

DISCUSSION
This is the largest study in pediatric and young adult kidney transplant recipients to describe
BP status based on 24-hour ABPM and to address the potential association of ambulatory
hypertension with allograft function and LVH.

Author Manuscript

This is also one of the first studies to characterize ABP in these patients according to the
revised 2014 AHA criteria. Using this classification, 36% of our cohort had masked or
sustained hypertension. However, more than a quarter of patients did not fit any BP category
and thus were unclassified, representing an important limitation of the AHA guidelines for
BP classification in pediatric kidney transplant recipients. Of note, in the only previously
published study classifying BP profiles according to the 2014 AHA criteria in this
population30, 15% of patients were also found to be unclassified. However, overall BP
control in that study, which analyzed patients 5-10 years post their kidney transplant, was
worse, with 39% of the patients having sustained hypertension.

Transplantation. Author manuscript; available in PMC 2018 January 01.
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Besides high rate of unclassified BP, the current AHA classification is very complicated
requiring interpretation of a wake or sleep, systolic or diastolic BP in six different
categories. Given these limitations and taking into account the high cardiovascular risk of
this population, we simplified the classification into four BP categories by using a lower
threshold (24-hour BP load ≥ 25%) as the cutoff to define ambulatory hypertension, a
method similarly utilized by the CKiD study in children with CKD10,11. This classification
broadens the definition of hypertension on one hand, including both patients with mean ABP
> 95th percentile (who have a BP load above 25% anyway) and patients with mean BP lower
than the 95th percentile but high BP load. On the other hand, the use of the 24h
measurements avoids defining all minor abnormalities (e.g. isolated nocturnal diastolic load
>25%) as hypertension. Of note, BP load is not incorporated in the adult AHA guidelines31,
but the use of the 25% BP load cutoff was discussed in the recent pediatric AHA guidelines,
which concluded that further study is needed to validate this approach.

Author Manuscript

Regardless of ABP classification, our study confirmed a high prevalence of masked
hypertension (25-32%) in children and young adults with a kidney transplant. This is similar
to or slightly higher that the prevalence of 19-31%, reported in previous studies14,16,18-20,30
although most of these studies reported a higher prevalence of sustained hypertension.
Importantly, even patients taking antihypertensive medications frequently were found to
have masked and sustained hypertension, suggesting that hypertension is both
underdiagnosed and inadequately treated in this population.

Author Manuscript

Both masked and sustained hypertension were more frequently seen in African-American or
Hispanic patients. While this cross-sectional analysis was not able to evaluate the effect of
abnormal ABP on long-term graft function and graft survival, previous studies showing that
African-American patients are at a higher risk for poor graft survival32,33 stress the
importance of better BP control in these patients.

Author Manuscript

Previous studies investigating the association of ABP status and cardiac structure in pediatric
kidney transplant recipients have reported inconsistent results. Some have found an
association of abnormal ABP status with LVMI, 4,13,20,29,34, with others did not confirm this
finding17,35,36. Given a large size of study population we were able to stratify patients
according to both ABP results and BP treatment and to clarify previous data of a higher
prevalence of LVH in patients with controlled hypertension (treated) compared with
normotensive patients not receiving BP medications. These results indicate that achieving
BP control with antihypertensive medications might not be enough to decrease the risk for
LVH. There are a few explanations for these results. First, it is possible that in many subjects
antihypertensive agents were initiated relatively recently, thus our data could reflect a delay
between the relatively prompt effect on blood pressure normalization and the slower effect
on cardiac structure. Alternatively, it may be the case that children who require
antihypertensives might need stricter BP control to maintain or achieve normal cardiac
geometry than children who do not require antihypertensive need. There also could be
additional, unrelated to hypertension mechanisms of cardiac hypertrophy in transplanted
patients. Finally, while in children taking antihypertensive medications had similar
prevalence of LVH regardless of the level of BP control, it is important to note that the

Transplantation. Author manuscript; available in PMC 2018 January 01.

Hamdani et al.

Page 8

Author Manuscript

highest frequency of LVH was seen in the small group of patients who had sustained
hypertension and were not taking antihypertensive medications.
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As in previous studies19,21,22, we found no significant association between ABP status and
graft function. However, as in the case of LVH, patients with normal BP who did not require
antihypertensive medications had less allograft dysfunction than patients taking
antihypertensives, even in those whose BP was within normal levels. This may reflect an
effect of previously untreated hypertension on worsening graft function and indicate the
need for more aggressive BP control at early stages after transplantation. Interestingly, in a
group not treated with antihypertensives, those with masked hypertension had similar graft
function to normotensive patients. One possible explanation for this finding is that BP
treatment is a surrogate marker for the duration of hypertension. Thus those with masked
hypertension and receiving antihypertensive medications may have had a longer duration of
uncontrolled BP than those with masked hypertension and not receiving antihypertensive
treatment. This is supported by the fact that among those off BP meds with masked
hypertension, the median time post-transplant was 2.7 years, while the median time posttransplant in patients on BP meds with masked hypertension was 4.5 years. Unfortunately
we did not have information to determine the duration of hypertension prior to ABPM.
Another limitation of our study is cross-sectional design so we could not assess a long-term
effect of masked hypertension on kidney function and cardiovascular outcomes.
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Echocardiographic results were not available for the entire cohort, and some of the available
ones were done up to 6 months before/after the ABP measurement; however, there was no
substantial difference in demographic and clinical parameters between patients with and
without echocardiograms. The variability in the methodology of CBP, echocardiographic
measurements, and kidney function determination among participating centers could also
affect the results of the study. Despite these limitations, our findings clearly demonstrate that
ambulatory hypertension is common and difficult to control in children and young adults
after kidney transplantation. The association of ambulatory hypertension with LVH
underscores the importance of early recognition of masked hypertension and supports the
case for ABPM and cardiac structure evaluation as a part of standard care in these patients.
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ABBREVIATIONS
ABP

ambulatory blood pressure

ABPM

ambulatory blood pressure monitoring

ACEI

angiotensin converting enzyme inhibitors

AHA

American Heart Association
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ARB

angiotensin receptor blockers

BP

blood pressure

CBP

casual blood pressure

CKD

chronic kidney disease

CV

cardiovascular

eGFR

estimated glomerular filtration rate

LVH

left ventricular hypertrophy

LVMI

left ventricular mass index

MWPNC

Midwest Pediatric Nephrology Consortium

WCH

white coat hypertension
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Figure 1.

Ambulatory blood pressure patterns according to the 2014 AHA (A) classification and based
on 24-hour blood pressure load cutoff to define hypertension (B) classification.
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Table 1

Author Manuscript

Patient Characteristics (n=221)
Age, y*
Age ≥18, n (%)

16.9 (13.9-19.4)
89 (39)

Male Gender, n (%)

136 (62)

Race, n (%)
White
African-American/Biracial
Hispanic
Other/Unknown

139 (63)
33 (15)
26 (12)
23 (10)

Age at Transplantation, y*

12 (7.3-15.1)

Time post Transplantation, y*

3.5 (1.3-7)

Author Manuscript

Primary Acquired Glomerular Disease, n (%)

51 (23)

First Transplant, n (%)

207 (94)

Living Donors, n (%)

130 (59)

Prior Dialysis, n (%)

145 (66)

History of Rejection, n (%)

57 (26)

Immunosuppression, n (%)
Calcineurin Inhibitors

176 (80)

Steroids

94 (43)

Mycophenolate Mofetil

170 (79)

Overweight/Obese, n (%)

78 (35)

Hemoglobin, g/dL*

12.2 (11.1-13.4)

Anemia, n (%)

47 (22)

Treated for hypertension, n (%)

153 (68)

Author Manuscript

§

46 (32)

LVH , n (%)
eGFR, Schwartz/CKD-EPI (ml/min/1.73m2)*
eGFR <60 ml/min/1.73m2, n (%)

68 (54-89)
83 (38)

*

Data are presented as median (IQR)

§

142 patients had echo data available for analysis

Author Manuscript
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Table 2

Author Manuscript

BP status (n=221)
SBP
Casual BP
mmHg, median (IQR)
BP index, median (IQR)
BP index ≥ 1.0, n (%)
24-hour BP
mmHg, median (IQR)
BP index, median (IQR)
BP index ≥ 1.0, n (%)
Load (%), median (IQR)
BP load >25%, n (%)

Author Manuscript

Day BP
mmHg, median (IQR)
BP index, median (IQR)
BP index ≥ 1.0, n, (%)
Load (%), median (IQR)
BP load >25%, n (%)

Night BP
mmHg, median (IQR)
BP index, median (IQR)
BP index ≥ 1.0, n (%)
Load (%), median (IQR)
BP load >25%, n (%)

Dipping
%, median (IQR)
Abnormal (<10%)

DBP

117 (108-124)

70 (62-77)

0.89 (0.83-0.95)
29 (13)

0.82 (0.73-0.91)
16 (7)

118 (110-125)

70 (66-74)

0.93 (0.86-0.98)

0.89 (0.83-0.95)

42 (19)

30 (14)

17 (4-38)
81 (37)

15 (7-34)
76 (34)

121 (114-129)

74 (69-79)

0.92 (0.86-0.97)
35 (16)

0.88 (0.82-0.94)
20 (9)

14 (3-35)

11 (3-28)

76 (34)

64 (29)

109 (102-117)

62 (57-67)

0.93 (0.88-1)

0.91 (0.85-0.98)

58 (26)

49 (22)

16 (0-47)
92 (42)

20 (7-40)
99 (45)

10 (6-14)
114 (52)

15 (9-21)
61 (28)

Author Manuscript
Author Manuscript
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Table 3

Author Manuscript

Association of BP Status with Patient Characteristics*
Normal
blood pressure
(n=114)

Masked
hypertension
(n=70)

17.2 (14.4-20)

17.4 (14.4-19.2)

Male Gender (%)

64 (56)

48 (69)

African-American/Hispanic, n (%)

20 (19)

Age**, years

Age at Transplantation**, years

a

26 (40)

Sustained
hypertension
(n=31)

a,b

14.4 (10.3-16.5)
19 (61)

a

11 (44)

a,b

Author Manuscript

12.4 (8.4-16)

12 (6.6-15.5)

Time post Transplantation**, years

3.5 (1.1-7)

3.9 (1.3-6.5)

Acquired Glomerular Disease, n (%)

27 (24)

16 (23)

8 (26)

Living Donors, n (%)

69 (61)

41 (59)

16 (52)

Prior Dialysis, n (%)

71 (63)

48 (70)

23 (74)

History of Rejection, n (%)

30 (26)

21 (30)

9 (29)

Calcineurin Inhibitors, n (%)

89 (80)

58 (83)

25 (86)

Steroids, n (%)

45 (41)

28 (40)

Overweight/Obese, n (%)

36 (32)

27 (39)

14 (45)

12 (10.9-13)

12.9 (11.6-13.6)

11.7 (10.9-13.2)

Anemia, n (%)

31 (27)

11 (16)

8 (26)

Treated for hypertension, n (%)

74 (65)

50 (71)

25 (81)

≥2 BP medications, n (%)

22 (20)

Hemoglobin**, g/dL,

LVMI (g/m2.7)

§

Author Manuscript

§

LVH, n (%)

eGFR, Schwartz/CKD-EPI**
(ml/min/1.73m2)
eGFR <60 ml/min/1.73m2, n (%)

a

24 (34)

34 (30-40)

37 (30-42)

21 (28)

14 (33)

70 (55-92)

69 (58-92)

43 (38)

22 (31)

9 (5.7-12.6)

3 (1.4-9.6)

a,b

18 (62)

a

11 (35)

a,b

40 (35-48)

a

11 (50)

a,b

59 (45-78)
16 (52)

*

Characteristics of patients with WCH (n=6) are not presented due to the small number

**

Data are presented as median (IQR)

a

p<0.05 compared with normal BP

b

p<0.05 versus masked HTN

§

139 patients had echo results available for analysis

Author Manuscript
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§

Author Manuscript

Author Manuscript

Author Manuscript
78 (65-96)

eGFR, ml/min/1.73m2
4 (67)b

51 (41-79)b

3/4 (75)

41 (39-43)

35 (30-40)

0.93 (0.91-0.95)

32 (16-50)

0.98 (0.94-1)

Sustained
hypertension
n=6 (9%)

Characteristics of patients with WCH (n=6) are not presented due to the small number

Data are presented as median (IQR)

1 (5)

81 (68-96)

5/13 (38)

a

39 (36-47)b

34 (21-47)

0.97 (0.93-0.99)

30 (19-43)

0.96 (0.93-0.99)

Masked
hypertension
n=20 (29%)

Off BP meds (n=68)

p<0.05 compared with normal BP and off BP meds

b

p=0.07 compared with patients with normal BP and off BP meds

a

§

*

4/29 (14)

LVH, n (%)

7 (18)

31 (29-37)

LVMI*, g/m2.7

eGFR <60 ml/min/1.73m2, n (%)

7 (3-14)

0.85 (0.79-0.88)

3 (0-12)

0.86 (0.81-0.91)

Normal
BP
n=40 (59%)

24H DBP load*, %

24 DBP Index*

24H SBP load*, (%)

24H SBP Index*

Variable

36 (49)b

61 (49-87)b

17/46 (37)b

37 (31-41)b

7 (4-13)

0.85 (0.81-0.88)

4 (2-12)

0.87 (0.94-0.91)

Controlled
hypertension
n=74 (48%)

21 (42)b

67 (54-89)b

9/29 (31)

34 (29-41)

31 (21-43)

0.95 (0.9-1)

40 (27-55)

0.98 (0.95-1.02)

Masked
hypertension
n=50 (33%)

On BP Meds (n=153)

Blood Pressure Parameters, LVH and Graft Function According to BP Treatment and BP Status

12 (48)b

62 (47-77)b

8/18 (44)b

40 (34-50)b

39 (27-73)

0.99 (0.92-1.08)

56 (48-89)

1.03 (0.98-1.1)

Sustained
hypertension
n=25 (16%)

Author Manuscript
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Table 5

Author Manuscript

Multivariable logistic regression analysis of factors associated with LVH
Estimate

Odds Ratio

Confidence
Interval

P value

Intercept

−2.35

Overweight/obese

1.29

3.6

1.6-8.0

0.002

Anemia

0.75

2.1

0.9-4.9

0.083

Hypertension

1.69

5.4

1.2-23.7

0.025

Antihypertensives

0.98

2.7

0.8-9.4

0.13

Hypertension*Antihypertensives

−1.74

0.2

0.03-0.99

0.05
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Table 6

Author Manuscript

Multivariable logistic regression analysis of factors associated with eGFR<60 ml/min/1.73m2
Estimate

Odds Ratio

Confidence
Interval

P value

Intercept

−1.96

Rejection

1.38

4.0

2.0-7.9

<0.001

Anemia

1.03

2.8

1.4-5.8

0.005

Antihypertensives

1.20

3.3

1.6-7.0

0.002

Hypertension

−0.12

0.9

0.5-1.6

0.699
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